Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial

Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker’s pipeline.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.